Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Recruiting, industry sponsors, Respiratory, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed277
7 trials
Showing 1 to 7, recently updated first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07600723 · 30 participants (planned) · Start Oct 8, 2026 · Primary completion Apr 3, 2028
Drug: Sotatercept; Background PAH Therapy · For: Pulmonary Arterial Hypertension
Sites: Hyderabad, India; Belagavi, India; Chennai, India
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsPivotal-lookingRecruiting
AOP Orphan Pharmaceuticals AGIndustry
NCT06317805 · 110 participants (planned) · Start Dec 6, 2023 · Primary completion Jun 2027
Drug: Generic treprostinil sodium + Standard of Care (Double Oral); Standard of Care - Double Oral · For: Pulmonary Arterial Hypertension
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; La Plata, Argentina · 28 sites in all
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.Pivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07053423 · 218 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 23, 2028
Drug: Dupilumab; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Miami, Florida; Cordele, Georgia · 85 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07587658 · 754 participants (planned) · Start Oct 6, 2026 · Primary completion Jul 30, 2028
Drug: dupilumab; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Mullica Hill, New Jersey
AstraZenecaAstraZeneca (AZN)
NCT06531798 · 166 participants (planned) · Start Jan 20, 2026 · Primary completion Oct 30, 2026
Drug: Breztri Aerosphere · For: Moderate to Severe COPD
Sites: Bangalore, India; Dalgate, Drugjan, India; Hyderabad, India · 6 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07073950 · 56 participants (planned) · Start Nov 24, 2025 · Primary completion May 31, 2027
Drug: Budesonide/Glycopyrronium/Formoterol Fumarate; Placebo · For: Chronic Obstructive Pulmonary Disease; Hyperinflation
Sites: Ahrensburg, Germany; Berlin, Germany; Frankfurt, Germany · 7 sites in all
- BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])Pivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07666490 · 644 participants (planned) · Start Jun 28, 2026 · Primary completion Jun 13, 2028
Drug: Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation); Foster® 200/6 pMDI (BDP/FF-200/6 µg) · For: Asthma
Sites: Rousse, Bulgaria
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.